Drug Approval | May 01, 2026
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Certification reinforces energy efficiency, sustainability goals, and green manufacturing across SMT’s Surat and Hyderabad facilities
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The Danish biotech company confirmed the global study will begin in the second half of 2026
Subscribe To Our Newsletter & Stay Updated
